ZURICH, Switzerland, June 2025 – Venture Valuation/Biotechgate (the “Company”) is delighted to announce its participation in the highly anticipated 2025 BIO International Convention taking place June 16-19, 2025, at the Boston Convention & Exhibition Center, in Boston, USA, as well as at RESI (Redefining Every Stage of Investment) Seed to Exit, at The Westin Copley Place in Boston on June 16.
The annual BIO International Convention, hosted by Biotechnology Innovation Organization (BIO), is the world’s largest industry gathering and brings together thousands of global biotechnology and biopharmaceutical leaders. The four-day event includes networking, programming and partnering opportunities.
The Company welcomes attendees to visit booth number 2345 in the Swiss Biotech Pavilion to learn more about its independent valuation services, life sciences database, and quarterly partnering events. Its team of experts will be available for discussions and to provide insights into solutions for the ever-evolving biotech landscape. Registered attendees can also schedule a one-on-one meetings with the Company’s delegates using the conference portal.
The Company Chief Executive Officer, Dr. Patrik Frei, and Senior Consultant, Dr. Gergely Iványi, will be presenting a course on the topic of “Product and Company Valuation” on June 15, 2025, also at the Boston Convention & Exhibition Center. The course will teach how to produce a valuation to be used in investment rounds, mergers and acquisitions, licensing deals, or strategic decisions in the life sciences industry.
The RESI conference series connects start-ups and investors and strategic channel partners. RESI maximizes fundraising companies’ efforts to find partners who are a fit for their technology and stage of development. RESI is uniquely cross-border and cross-domain, connecting start-ups with 10 categories of global investors across the silos of drugs, devices, diagnostics and digital health (4 Ds). RESI caters to both the earliest stage start-ups, those seeking grants, seed and angel capital, and the early-stage firms who seek series A and B funding. RESI is a unique and powerful tool for sourcing assets and advancing innovation across early-stage life science and healthcare. Patrik Frei will also present at RESI on valuation for fundraising.
On Wednesday, June 18, Patrik Frei will participate on a breakfast panel covering “Beyond Venture Capital – Alternative Financial Strategies for Biotech Growth” organized by the Swiss Business Hub USA. Registration: https://my.businesslocation.swiss/bio2025
The Biotechgate team will also be present at the BIO International Convention, providing insights into the renowned business development database and its newly launched AI-supported semantic search feature.
About Venture Valuation:
Venture Valuation was founded in 1999 based on profound research work by the founder and CEO, Dr. Patrik Frei, at the University of St. Gallen (HSG) and the Swiss Federal Institute of Technology in Lausanne (EPFL). The company has remained true to its mission: the independent assessment and valuation of companies, products and assets.
The focus lies on technology companies in fast-growing markets and industries including pharmaceuticals, biotechnology, medical technology, nanotechnology, renewable energies and information technology / computer science / software. Clients include both, investors as well as finance-seeking companies themselves, and are domiciled on almost all continents. Over the course of more than two decades, key strengths and expertise have been built in the life sciences industry.
About Biotechgate:
Biotechgate is a leading business development and licensing database for the entire life science industry, offering a wealth of information on over 65,000 life science company profiles. Thanks to its unique data-sourcing process, the profiles include company descriptions, contact information, product pipeline information, financing rounds, and management details, making it an invaluable resource for big pharma, start-ups, investors, and other industry professionals. Biotechgate also features 40,000 licensing deals and a clinical trials database containing over 1 million records from registries around the world.